Format

Send to

Choose Destination
Breast Cancer Res. 2012 Jan 19;14(1):202.

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance.

Author information

1
Methodist Hospital Cancer Center, 6550 Fannin Street SM383, Houston, TX 77030, USA.

Abstract

Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.

PMID:
22264257
PMCID:
PMC3496111
DOI:
10.1186/bcr2938
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center